A Phase 2 interventional study of cemiplimab and fianlimab in Cutaneous Squamous Cell Carcinoma, sponsored by Regeneron Pharmaceuticals. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-26.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is researching an investigational drug called REGN2810, also known as cemiplimab, and when combined with another investigational drug called REGN3767, also known as fianlimab (each individually called a "study drug" or called "study drugs" when combined). The study is focused on a type of skin cancer known as cutaneous squamous cell carcinoma (CSCC).
The aim of the study is to see if cemiplimab or cemiplimab in combination with fianlimab can eliminate or reduce the number of living cancer cells in tumor(s) if taken before surgery.
The study is looking at several other research questions, including:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol-defined Inclusion/Exclusion Criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: cemiplimab
Drug: cemiplimab · Drug: fianlimab
Administered Intravenous (IV) infusion every three weeks (Q3W)
Also known as: REGN2810, Libtayo
IV infusion Q3W
Also known as: REGN3767
Pathological complete response (pCR) rate by blinded independent pathological review (BIPR)
Time frame: Up to 100 days
pCR rate by local pathological review
Time frame: Up to 100 days
Major pathological response (MPR)
Time frame: Up to 100 days
Event-free survival (EFS)
Time frame: Up to 3 years
Disease free survival (DFS)
Time frame: Up to 3 years
Objective response rate (ORR) prior to surgery
Time frame: Up to 100 days
Overall survival (OS)
Time frame: Up to 3 years
Occurrence of treatment-emergent adverse events (TEAEs)
Time frame: Up to 3 years
Occurrence of immune-mediated adverse events (imAEs)
Time frame: Up to 3 years
Occurrence of treatment-related TEAEs
Time frame: Up to 3 years
Occurrence of adverse event of special interest (AESI)
Time frame: Up to 3 years
Occurrence of treatment-emergent serious adverse events (SAEs)
Time frame: Up to 3 years
Occurrence of laboratory abnormalities
Per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0
Time frame: Up to 3 years
Occurrence of death due to TEAE
Time frame: Up to 3 years
Occurrence of interruption of study drug(s) due to TEAEs
Time frame: Up to 3 years
Occurrence of discontinuation of study drug(s) due to TEAEs
Time frame: Up to 3 years
Occurrence of cancellation of surgery due to TEAE
Time frame: Up to 100 days
Occurrence of delay to surgery due to TEAE
Time frame: Up to 100 days
Concentrations of cemiplimab in serum
Time frame: Up to 3 years
Concentrations of fianlimab in serum
Time frame: Up to 3 years
Concentrations of other experimental agents (as applicable) in serum
Time frame: Up to 3 years
Incidence of anti-drug antibodies (ADA) to cemiplimab
Time frame: Up to 3 years
Incidence of ADA to fianlimab
Time frame: Up to 3 years
Incidence of ADA to other experimental agents (as applicable)
Time frame: Up to 3 years
Titer of ADA to cemiplimab
Time frame: Up to 3 years
Titer of ADA to fianlimab
Time frame: Up to 3 years
Titer of ADA to other experimental agents (as applicable)
Time frame: Up to 3 years
No study locations are listed for this record.
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Start is estimated for Nov 2024; primary completion for Jun 2026, 18 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cemiplimab